<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://allsci.com/news/regulatory/ap301-hyperphosphatemia-dialysis-chinas-nmpa/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-07T16:31:47.404147Z</news:publication_date>
      <news:title>China accepts NDA for Alebund&apos;s phosphate binder AP301 after Phase III success</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/regulatory/fda-fast-track-ovarian-cancer-bioinvent-secures/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-07T16:28:01.316068Z</news:publication_date>
      <news:title>BioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer data</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/first-in-human-trials/triple-agonist-obesity-neurocrine-launches-for/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-07T16:26:00.345852Z</news:publication_date>
      <news:title>Neurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/approvals/benmelstobart-squamous-lung-cancer-cttqs/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-07T16:21:02.020286Z</news:publication_date>
      <news:title>Sino Bio&apos;s benmelstobart-anlotinib regimen adds new China indication in first-line squamous NSCLC</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/licensing-and-partnerships/arcturus-csl-seqirus-settlement-unwinds-usd-43/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-07T16:13:37.918464Z</news:publication_date>
      <news:title>Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/bmn-401-discontinued-biomarin-discontinues-after/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-07T16:01:43.595151Z</news:publication_date>
      <news:title>BioMarin drops BMN 401 following unsuccessful pivotal trial</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/licensing-and-partnerships/rna-editing-rett-syndrome-shape-and-research/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-07T15:03:13.253864Z</news:publication_date>
      <news:title>Shape and Rett Syndrome Research Trust advance AI-designed RNA editor for R168X mutation</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/pipe-financing/tarsus-alkeus-acquisition-funding-secures-usd/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-07T14:59:09.756698Z</news:publication_date>
      <news:title>Tarsus secures USD 125m to fund Alkeus acquisition and expand eye care pipeline</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/first-in-human-trials/disp-10-immunotherapy-trial-dispatch-bio-launches/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-07T14:50:34.925834Z</news:publication_date>
      <news:title>Dispatch advances synthetic-antigen CAR T platform into first-in-human testing</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://allsci.com/news/clinical-trials/fasedienol-social-anxiety-shows-numerical/</loc>
    <news:news>
      <news:publication><news:name>AllSci</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-08-07T14:39:45.790307Z</news:publication_date>
      <news:title>Vistagen reports exploratory Phase II miss for social anxiety drug candidate</news:title>
    </news:news>
  </url>
</urlset>